Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase 2

Active, not recruiting

Conditions: Lymphoproliferative Disorder
HIV
HHV-8
Malignancy

Interventions: Drug: Etoposide
Drug: Interferon-alpha
Other: Observation Only
Drug: Sirolimus
Drug: Zidovudine
Drug: Rituximab
Drug: Bortezomib
Drug: Doxorubicin
Drug: Liposomal Doxorubicin
Drug: Valganciclovir
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Filgrastim (G-CSF)
Drug: Prednisone

First Posted Date: 2004-09-22

Last Posted Date: 2024-12-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00092222

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-09-16

Last Posted Date: 2013-05-30

Lead Sponsor: Loyola University

Registration Number: NCT00004905

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-09-16

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004172

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Phase 1

Conditions: Chronic Myeloproliferative Disorders
Drug/Agent Toxicity by Tissue/Organ
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-09-13

Last Posted Date: 2013-12-19

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 30

Registration Number: NCT00004036

Locations: 🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: thioguanine
Drug: vincristine sulfate

First Posted Date: 2004-09-13

Last Posted Date: 2014-07-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 59

Registration Number: NCT00003671

Locations: 🇺🇸
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸
Madigan Army Medical Center, Tacoma, Washington, United States

and more 54 locations

Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: tirapazamine

First Posted Date: 2004-09-13

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00003288

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 25 locations

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Phase 1

Terminated

Conditions: Kidney Neoplasms

First Posted Date: 2004-09-13

Last Posted Date: 2012-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00091611

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-09-08

Last Posted Date: 2012-03-15

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 136

Registration Number: NCT00091104

Locations: 🇺🇸
NCI - Surgery Branch, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Combination Chemotherapy in Treating Patients With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel

First Posted Date: 2004-09-06

Last Posted Date: 2020-04-29

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 2005

Registration Number: NCT00003088

Locations: 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States

and more 16 locations

Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: methotrexate
Drug: vincristine sulfate

First Posted Date: 2004-09-06

Last Posted Date: 2014-07-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 20

Registration Number: NCT00003217

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Chicago, Illinois, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy